Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0530 vs Zoledronic Acid in Metastatic Bone Disease
NCT00558272Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of saracatinib in metastatic bone disease (MBD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen at 4 weeks. Started Feb 2008; status: completed.
02
Drugs
saracatinib
03
Conditions
metastatic bone disease (MBD)
Beyond the preview
Go deeper on NCT00558272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558272.